gemtuzumab ozogamicin
Selected indexed studies
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. (Haematologica, 2019) [PMID:30076173]
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. (Lancet Oncol, 2014) [PMID:25008258]
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. (Lancet, 2012) [PMID:22482940]
_Worker-drafted node — pending editorial review._
Connections
gemtuzumab ozogamicin is a side effect of
Sources
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. (2019) pubmed
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. (2014) pubmed
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. (2012) pubmed
- Gemtuzumab ozogamicin. (2001) pubmed
- Gemtuzumab ozogamicin in AML: the next chapter. (2023) pubmed
- Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future. (2020) pubmed
- Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. (2021) pubmed
- Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. (2014) pubmed
- Gemtuzumab ozogamicin in acute myeloid leukemia. (2017) pubmed
- Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. (2018) pubmed